GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine.
Identifieur interne : 004202 ( PubMed/Checkpoint ); précédent : 004201; suivant : 004203GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine.
Auteurs : M. Merello [Argentine] ; A J Lees ; J. Balej ; A. Cammarota ; R. LeiguardaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1999.
English descriptors
- KwdEn :
- Action Potentials (drug effects), Action Potentials (physiology), Apomorphine (pharmacology), Apomorphine (therapeutic use), Basal Ganglia (drug effects), Dopamine Agonists (pharmacology), Dopamine Agonists (therapeutic use), Dose-Response Relationship, Drug, Globus Pallidus (drug effects), Globus Pallidus (surgery), Humans, Male, Middle Aged, Monitoring, Intraoperative, Neurons (drug effects), Parkinson Disease (drug therapy), Psychomotor Performance (drug effects), Stereotaxic Techniques, Thalamus (drug effects), Time Factors.
- MESH :
- chemical , pharmacology : Apomorphine, Dopamine Agonists.
- drug effects : Action Potentials, Basal Ganglia, Globus Pallidus, Neurons, Psychomotor Performance, Thalamus.
- drug therapy : Parkinson Disease.
- physiology : Action Potentials.
- surgery : Globus Pallidus.
- chemical , therapeutic use : Apomorphine, Dopamine Agonists.
- Dose-Response Relationship, Drug, Humans, Male, Middle Aged, Monitoring, Intraoperative, Stereotaxic Techniques, Time Factors.
Abstract
We present a patient with clinically evident beginning-of-dose motor deterioration who had undergone posteroventral pallidotomy. This patient underwent an intrasurgical apomorphine test followed by single cell recording of the internal globus pallidus (GPi) to determine changes in GPi firing rate during the occurrence of such phenomenon. A significant increase in GPi firing rate coincident with worsening of patient disabilities prior to improvement was found. This finding suggests that beginning-of-dose motor deterioration may be mediated by enhanced thalamic inhibition.
PubMed: 10348473
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:10348473Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine.</title><author><name sortKey="Merello, M" sort="Merello, M" uniqKey="Merello M" first="M" last="Merello">M. Merello</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI), Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI), Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name></author><author><name sortKey="Balej, J" sort="Balej, J" uniqKey="Balej J" first="J" last="Balej">J. Balej</name></author><author><name sortKey="Cammarota, A" sort="Cammarota, A" uniqKey="Cammarota A" first="A" last="Cammarota">A. Cammarota</name></author><author><name sortKey="Leiguarda, R" sort="Leiguarda, R" uniqKey="Leiguarda R" first="R" last="Leiguarda">R. Leiguarda</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10348473</idno><idno type="pmid">10348473</idno><idno type="wicri:Area/PubMed/Corpus">004200</idno><idno type="wicri:Area/PubMed/Curation">004200</idno><idno type="wicri:Area/PubMed/Checkpoint">004202</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine.</title><author><name sortKey="Merello, M" sort="Merello, M" uniqKey="Merello M" first="M" last="Merello">M. Merello</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI), Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI), Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name></author><author><name sortKey="Balej, J" sort="Balej, J" uniqKey="Balej J" first="J" last="Balej">J. Balej</name></author><author><name sortKey="Cammarota, A" sort="Cammarota, A" uniqKey="Cammarota A" first="A" last="Cammarota">A. Cammarota</name></author><author><name sortKey="Leiguarda, R" sort="Leiguarda, R" uniqKey="Leiguarda R" first="R" last="Leiguarda">R. Leiguarda</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Action Potentials (drug effects)</term><term>Action Potentials (physiology)</term><term>Apomorphine (pharmacology)</term><term>Apomorphine (therapeutic use)</term><term>Basal Ganglia (drug effects)</term><term>Dopamine Agonists (pharmacology)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Globus Pallidus (drug effects)</term><term>Globus Pallidus (surgery)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Monitoring, Intraoperative</term><term>Neurons (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Psychomotor Performance (drug effects)</term><term>Stereotaxic Techniques</term><term>Thalamus (drug effects)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Apomorphine</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Action Potentials</term><term>Basal Ganglia</term><term>Globus Pallidus</term><term>Neurons</term><term>Psychomotor Performance</term><term>Thalamus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Action Potentials</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Globus Pallidus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Apomorphine</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Monitoring, Intraoperative</term><term>Stereotaxic Techniques</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We present a patient with clinically evident beginning-of-dose motor deterioration who had undergone posteroventral pallidotomy. This patient underwent an intrasurgical apomorphine test followed by single cell recording of the internal globus pallidus (GPi) to determine changes in GPi firing rate during the occurrence of such phenomenon. A significant increase in GPi firing rate coincident with worsening of patient disabilities prior to improvement was found. This finding suggests that beginning-of-dose motor deterioration may be mediated by enhanced thalamic inhibition.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">10348473</PMID><DateCreated><Year>1999</Year><Month>09</Month><Day>17</Day></DateCreated><DateCompleted><Year>1999</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>1999</Year><Month>May</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine.</ArticleTitle><Pagination><MedlinePgn>481-3</MedlinePgn></Pagination><Abstract><AbstractText>We present a patient with clinically evident beginning-of-dose motor deterioration who had undergone posteroventral pallidotomy. This patient underwent an intrasurgical apomorphine test followed by single cell recording of the internal globus pallidus (GPi) to determine changes in GPi firing rate during the occurrence of such phenomenon. A significant increase in GPi firing rate coincident with worsening of patient disabilities prior to improvement was found. This finding suggests that beginning-of-dose motor deterioration may be mediated by enhanced thalamic inhibition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Merello</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lees</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Balej</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cammarota</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Leiguarda</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000200">Action Potentials</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001058">Apomorphine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001479">Basal Ganglia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005917">Globus Pallidus</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016343">Monitoring, Intraoperative</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011597">Psychomotor Performance</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013238">Stereotaxic Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013788">Thalamus</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>5</Month><Day>29</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>5</Month><Day>29</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10348473</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Argentine</li></country></list><tree><noCountry><name sortKey="Balej, J" sort="Balej, J" uniqKey="Balej J" first="J" last="Balej">J. Balej</name><name sortKey="Cammarota, A" sort="Cammarota, A" uniqKey="Cammarota A" first="A" last="Cammarota">A. Cammarota</name><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name><name sortKey="Leiguarda, R" sort="Leiguarda, R" uniqKey="Leiguarda R" first="R" last="Leiguarda">R. Leiguarda</name></noCountry><country name="Argentine"><noRegion><name sortKey="Merello, M" sort="Merello, M" uniqKey="Merello M" first="M" last="Merello">M. Merello</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004202 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004202 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:10348473
|texte= GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:10348473" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |